Suppliers / Formosa Laboratories

Formosa Laboratories

Taiwan 4746.TW 199 employees 2 duplicate records merged Updated 9 July 2026

Formosa Laboratories is an API manufacturer based in Taiwan. It holds 51 active US drug master files and 8 valid CEPs. Its GMP standing is certified by EMA and US FDA. Its most recent recorded inspection, by US FDA, closed on 25 July 2024 as VAI.

51
active US DMFs
8
valid CEPs
2
registered plants 1 with an FDA FEI number
2
filings across 1 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
6 of 6 confirmed
EU GMP
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026. EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.

Inspection history

  • 25 July 2024 VAI US FDA
  • 11 November 2022 NAI US FDA
  • 9 November 2018 VAI US FDA
  • 22 January 2015 NAI US FDA
  • 10 May 2012 NAI US FDA
  • 18 June 2009 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Taoyuan, Taiwan Not on file
Taiwan, Taiwan 3003420376

What they file, and where

Molecule Regulators Docs
Calcipotriol EDQM, SFDA (Saudi Arabia), US FDA 6
Calcitriol EDQM, US FDA 3
Sevelamer US FDA 3
Sevelamer Carbonate SFDA (Saudi Arabia) 3
Temozolomide EDQM, SFDA (Saudi Arabia), US FDA 3
Calcifediol EDQM, US FDA 2
Capsaicin SFDA (Saudi Arabia), US FDA 2
Colesevelam US FDA 2
Leflunomide EDQM, US FDA 2
Linezolid SFDA (Saudi Arabia), US FDA 2
Show all 30 molecules on file
Montelukast EDQM, US FDA 2
Mycophenolic Acid US FDA 2
Nintedanib US FDA 2
Paricalcitol SFDA (Saudi Arabia), US FDA 2
Teriflunomide SFDA (Saudi Arabia), US FDA 2
Abemaciclib US FDA 1
Anastrozole US FDA 1
Apraclonidine US FDA 1
Balsalazide US FDA 1
Benzonatate US FDA 1
Capivasertib US FDA 1
Colestipol US FDA 1
Dinalbuphine Sebacate US FDA 1
Doxercalciferol US FDA 1
Elagolix US FDA 1
Ergocalciferol US FDA 1
Eribulin US FDA 1
Ferric Carboxymaltose US FDA 1
Fondaparinux US FDA 1
Gadobutrol US FDA 1

Also appears on these molecule pages

Filings and GMP by regulator

Regulator Filings GMP certificates
MINSA (CR) 2 None
EMA None 2
US FDA None 1

Comparing suppliers?

Choose your molecules and target markets. Formosa Laboratories comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • 2 active litigation matters are on record.
  • The most recent inspection outcome was VAI, on 25 July 2024.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates